PET Imaging Tracer for Brain Neuropeptide Y2 Receptors Faces Rapid Metabolism and Blood-Brain Barrier Challenges in Mice | Research

The takeaway

A selective NPY2 receptor PET tracer shows nanomolar binding affinity but is rapidly metabolized and actively pumped out of the brain by P-glycoprotein, requiring P-gp inhibition for successful imaging.

3-fold brain uptake increase with P-gp block
Tariquidar pretreatment tripled brain tracer concentrations in hippocampus, thalamus, and striatum, proving P-glycoprotein efflux is the main barrier to NPY2R imaging

What the researchers found

N-[11C]methyl-(R)-JNJ-31020028 showed nanomolar affinity and high selectivity for murine NPY2R with no interaction with Y1, Y4, or Y5 subtypes. However, brain uptake peaked within 5 minutes and declined rapidly. P-glycoprotein inhibition with tariquidar increased brain uptake more than 3-fold at 15 minutes in hippocampus, thalamus, and striatum. Rapid peripheral metabolism left no intact tracer in the brain at 60 minutes in vehicle-treated mice. Metabolite-corrected brain-to-plasma ratios confirmed negligible tracer uptake without P-gp blockade. The study concludes that P-gp-mediated efflux is a major barrier to NPY2R imaging.

Why it matters

Visualizing neuropeptide receptors in the living brain is essential for understanding psychiatric and metabolic disorders and for developing new drugs. NPY2R is implicated in anxiety, depression, PTSD, and eating disorders, but no PET tracer has successfully imaged it in clinical practice. This study identifies the specific obstacles (rapid metabolism and P-gp efflux) that must be overcome, providing a roadmap for developing next-generation NPY2R tracers that could eventually enable human brain imaging studies.

How the study worked

In vitro binding assays confirmed tracer selectivity for murine NPY2R versus Y1, Y4, and Y5 receptors. In vivo PET imaging in C57BL/6J mice measured brain uptake over time with and without tariquidar (P-gp inhibitor) pretreatment. Radiometabolite analysis was performed on plasma and brain samples. Brain regional analysis focused on hippocampus, thalamus, and striatum. Metabolite-corrected brain-to-plasma concentration ratios were calculated.

What this study cannot tell us

The study was conducted entirely in mice, and P-gp expression levels and metabolic pathways differ between mice and humans. Tariquidar co-administration is not clinically practical for routine PET imaging. The tracer's rapid metabolism makes it unsuitable for clinical use in its current form. Brain region-specific NPY2R binding could not be properly quantified due to the low signal without P-gp inhibition.

How to read the evidence

This is a rigorous preclinical tracer evaluation study with comprehensive in vitro selectivity data, in vivo PET imaging, and radiometabolite analysis. The findings clearly characterize the tracer's limitations and provide actionable insights for future development.

When this study was published

Published in 2025, this study represents the current state of efforts to develop PET tracers for the neuropeptide Y system — an area with significant unmet need in neuropsychiatric imaging.

The bigger picture

PET imaging of neuropeptide receptors is one of the most challenging frontiers in neuroimaging. While tracers exist for dopamine, serotonin, and opioid receptors, the neuropeptide Y system remains largely invisible to in vivo imaging. Overcoming the P-gp barrier is a common challenge — many neuropeptide receptor ligands are P-gp substrates. This study advances the field by precisely characterizing the obstacles, which will guide the design of improved tracers and potentially inform drug development for NPY-targeted therapies.

Questions still open

Can next-generation NPY2R tracers be designed with P-gp resistance and improved metabolic stability?
Would a fluorine-18-labeled version with a longer half-life provide better imaging windows?
Could this tracer still be useful with P-gp inhibition protocols for preclinical NPY2R research?

Common questions

Why is it so hard to image neuropeptide receptors in the brain?

Two main challenges: First, the blood-brain barrier actively pumps out many molecules using P-glycoprotein efflux pumps — this study showed that P-gp removed over two-thirds of the tracer from the brain. Second, the body rapidly breaks down the tracer (metabolism), so there isn't enough intact tracer to produce a clear signal. These challenges are particularly tough for neuropeptide receptor tracers because many neuropeptide ligands are natural P-gp substrates.

Why would doctors want to see neuropeptide Y receptors in the brain?

The neuropeptide Y system plays key roles in anxiety, depression, PTSD, stress responses, and eating behavior. Being able to see Y2 receptors in living human brains with PET scans could help diagnose psychiatric disorders, predict treatment responses, and test whether new drugs are actually reaching their brain targets. It could also reveal how the NPY system changes in obesity, eating disorders, and chronic stress.

Read the original research

Evaluating methodological constraints in PET imaging of neuropeptide Y2 receptors with N-[11C]-methyl-(R)-JNJ-31020028 in brains of C57BL/6J mice.

EJNMMI radiopharmacy and chemistry, 11(1), 1

View on PubMed ↗Publisher’s paper ↗

Citation

Bamminger, Karsten; Fernandes, Eduardo Felipe Alves; Zachhuber, Lena; Lopez-Martinez, Ines; Kuntner, Claudia; Langer, Oliver; Mairinger, Severin; Christoffersen, Berit Ø; Hacker, Marcus; Wanek, Thomas. (2025). Evaluating methodological constraints in PET imaging of neuropeptide Y2 receptors with N-[11C]-methyl-(R)-JNJ-31020028 in brains of C57BL/6J mice.. EJNMMI radiopharmacy and chemistry, 11(1), 1. https://doi.org/10.1186/s41181-025-00407-x